Who are Theolytics's investors?

Theolytics's investors include Epidarex Capital, Oxford Science Enterprises, Sound Bioventures, Taiho Ventures, LLC, M Ventures.

Theolytics

5 known investors

Find your way into Theolytics

Paths you didn't know you had: your email and LinkedIn already hold routes to the Theolytics team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Theolytics develops systemically deliverable immunotherapies based on oncolytic adenoviruses designed to target solid tumours and their supporting microenvironment. It uses its Adenovo platform to screen large libraries of adenovirus variants in human systems to identify therapeutic candidates, with THEO-260 as its lead programme.

Biotech Healthtech

Investors · 5

Epidarex Capital✓ confirmed by TheolyticsBethesda · $2.5M – $6.3M

How we know: Epidarex Capital's portfolio page · the company's own site · open dataset · 5k.vc investor directory · Not right? Tell us

Oxford Science Enterprises✓ confirmed by TheolyticsOxford · $63.5K – $31.8M

How we know: the company's own site · Oxford Science Enterprises's portfolio page · Not right? Tell us

Sound Bioventures✓ confirmed by TheolyticsMalmö

How we know: the company's own site · the VCSheet dataset · Not right? Tell us

Taiho Ventures, LLC✓ confirmed by TheolyticsMenlo Park

How we know: the company's own site · Not right? Tell us

M Ventureslisted by M VenturesAmsterdam · $10.8M

How we know: a partner's Signal profile · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

Founder mafia

2 people who came through Theolytics went on to found or lead other companies.

Mike GreyExecutive ChairFounded Auspex Pharmaceuticals Henning SteinhagenBoard Director and Co-lead investorFounded Symeres

Frequently asked questions

What does Theolytics do?: Theolytics develops systemically deliverable immunotherapies based on oncolytic adenoviruses designed to target solid tumours and their supporting microenvironment. It uses its Adenovo platform to screen large libraries of adenovirus variants in human systems to identify therapeutic candidates, with THEO-260 as its lead programme.
Who are Theolytics's investors?: Theolytics's investors include Epidarex Capital, Oxford Science Enterprises, Sound Bioventures, Taiho Ventures, LLC, M Ventures.